BGB-24714 + Combination Therapies for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a drug called BGB-24714, alone or with other treatments, for people with advanced solid tumors. The goal is to find the highest safe dose to use in future studies.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on corticosteroids or other immunosuppressive medications, you must have stopped them at least 14 days before starting the trial.
Is BGB-24714 and its combination therapies safe for humans?
The safety of BGB-24714 specifically is not directly addressed in the provided research articles. However, combination therapies in cancer treatment often have different safety profiles, and some studies indicate that combination therapies can have serious adverse events. It's important to consult with healthcare professionals for detailed safety information specific to BGB-24714.12345
What makes the drug BGB-24714 unique for treating solid tumors?
What data supports the effectiveness of the drug BGB-24714 in combination with other therapies for solid tumors?
While there is no direct data on BGB-24714, research shows that combining different cancer treatments, like immunotherapy and targeted therapies, can enhance their effectiveness. For example, combining bevacizumab with chemotherapy has shown improved survival in lung cancer patients, suggesting that similar combination strategies might be beneficial for other solid tumors.1112131415
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors that have grown or spread despite standard treatments, or when no treatment options are available. Participants must be in relatively good health and physical condition (ECOG ≤1), able to provide a tumor tissue sample, and not have had certain other cancers or major surgeries recently. They also can't be on steroids or similar meds within 14 days of starting the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of BGB-24714 as monotherapy or in combination with chemoradiation or paclitaxel
Dose Expansion
BGB-24714 is administered in combination with paclitaxel or docetaxel in participants with selected solid tumors
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BGB-24714
- Paclitaxel
BGB-24714 is already approved in China for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
BeiGene
Lead Sponsor